Abstract
African trypanosomes express a glycosylphosphatidyl inositol (GPI)-anchored variant-specific surface glycoprotein (VSG) as a protective coat. During infection, large amounts of VSG molecules are released into the circulation. Their interaction with various cells of the immune system underlies the severe infection-associated pathology. Recent results have shown that anti-GPI vaccination can prevent the occurrence of this pathology.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Africa
-
Animals
-
Glycosylphosphatidylinositols / chemistry
-
Glycosylphosphatidylinositols / immunology*
-
Glycosylphosphatidylinositols / physiology*
-
Humans
-
Macrophage Activation
-
Macrophages / immunology*
-
Macrophages / metabolism
-
Trypanosoma brucei gambiense / immunology
-
Trypanosoma brucei gambiense / pathogenicity
-
Trypanosoma brucei rhodesiense / immunology
-
Trypanosoma brucei rhodesiense / pathogenicity
-
Trypanosomiasis / immunology*
-
Trypanosomiasis / metabolism
-
Trypanosomiasis / physiopathology*
-
Trypanosomiasis / veterinary
-
Type C Phospholipases / metabolism
-
Vaccination
-
Variant Surface Glycoproteins, Trypanosoma / chemistry
-
Variant Surface Glycoproteins, Trypanosoma / immunology*
-
Variant Surface Glycoproteins, Trypanosoma / physiology*
Substances
-
Glycosylphosphatidylinositols
-
Variant Surface Glycoproteins, Trypanosoma
-
Type C Phospholipases